Valuation: IMPACT Therapeutics, Inc

Market Cap 306.63Cr 356.25Cr 45Cr 39Cr 37Cr 34Cr 64Cr 4.32TCr 64Cr 430.9Cr 169.12Cr 2.16TCr 170.58Cr 166.82Cr 7.16TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 222.4Cr 258.39Cr 33Cr 29Cr 27Cr 24Cr 46Cr 3.13TCr 47Cr 312.53Cr 122.66Cr 1.57TCr 123.72Cr 120.99Cr 5.19TCr EV / Sales 2026 *
7.73x
EV / Sales 2027 * 1.89x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-6.90%
1 week+4.25%
Current month-9.22%
1 month-41.41%
1 week 11.42
Extreme 11.42
13.5
1 month 10.31
Extreme 10.31
21
Current year 10.31
Extreme 10.31
47.98
1 year 10.31
Extreme 10.31
47.98
3 years 10.31
Extreme 10.31
47.98
5 years 10.31
Extreme 10.31
47.98
10 years 10.31
Extreme 10.31
47.98
Manager TitleAgeSince
Chief Executive Officer 69 01/06/2014
Director of Finance/CFO 51 01/05/2024
Chief Tech/Sci/R&D Officer 44 01/01/2025
Director TitleAgeSince
Director/Board Member 69 01/06/2014
Director/Board Member 69 01/06/2014
Director/Board Member 44 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%+4.25% - - 45Cr
+0.53%-0.53%+4.00%+15.71% 4.86TCr
+1.98%+9.05%+413.94%+532.17% 4.19TCr
+3.44%-4.65%+28.34%+8.81% 3.89TCr
+1.40%+0.10%+6.61%+61.93% 3.72TCr
+2.42%+5.72%+12.38%+44.79% 3.07TCr
-0.16%-3.11% - - 1.61TCr
+2.20%+0.48%+34.71%+127.15% 1.64TCr
+0.26%+1.84%+8.14%+18.97% 1.4TCr
+4.25%-8.23%-1.49%-35.46% 1.26TCr
Average +0.94%+0.08%+63.33%+96.76% 2.57TCr
Weighted average by Cap. +1.78%-0.10%+83.03%+120.75%

Financials

2026 *2027 *
Net sales 29Cr 33Cr 4.26Cr 3.69Cr 3.44Cr 3.16Cr 5.97Cr 404.98Cr 6.04Cr 40Cr 16Cr 202.63Cr 16Cr 16Cr 671.1Cr 94Cr 109.36Cr 14Cr 12Cr 11Cr 10Cr 20Cr 1.33TCr 20Cr 132.28Cr 52Cr 663.33Cr 52Cr 51Cr 2.2TCr
Net income - -
Net Debt -84Cr -98Cr -12Cr -11Cr -10Cr -9.26Cr -17Cr -1.19TCr -18Cr -118.37Cr -46Cr -593.59Cr -47Cr -46Cr -1.97TCr -128.75Cr -149.59Cr -19Cr -17Cr -15Cr -14Cr -27Cr -1.81TCr -27Cr -180.93Cr -71Cr -907.32Cr -72Cr -70Cr -3TCr
Logo IMPACT Therapeutics, Inc
IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.
Employees
-
Date Price Change Volume
06/26/06 HK$12.01 -6.90% 7,24,696
05/26/05 HK$12.90 +6.35% 5,57,159
04/26/04 HK$12.13 +4.57% 5,76,212
03/26/03 HK$11.60 -12.32% 5,69,480
31/26/31 HK$13.23 +14.84% 8,07,400
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
11.10CNY
Average target price
28.52CNY
Spread / Average Target
+156.83%

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7630 Stock